Intrauterine hormonal levonorgestrel-releasing system in women in perimenopause
- Authors: Prilepskaya VN1, Abakarova PR1, Prilepskaya V1, Abakarova P1
-
Affiliations:
- Issue: No 1 (2010)
- Pages: 17-21
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/278186
- ID: 278186
Cite item
Full Text
Abstract
We review the literature data devoted to use of the intrauterine levonorgestrel-releasing system (LNG-IUS), an effective method of prevention of unwanted pregnancies in women of reproductive age and fertile perimenopausal women with ovulatory menstrual cycles. It is also possible the use of LNG-IUS as ultra low dose hormone progestin component of hormone replacement therapy (HRT) with estrogens. The selection criteria for the use of LNG-IUD in premenopausal women as the progestin component of HRT are the presence of symptoms of climacteric syndrome, anovulation, and oligomenorrhea. The use of LNG-IUD in patients with hyperplastic processes of endometrium and breast, as well as dysmenorrhea, premenstrual syndrome, menorrhagia, endometriosis, premenstrual syndrome, anemia is most reasonable.
References
- Прилепская В.Н. Руководство по контрацепции. М.: Медпресс-информ, 2006.
- Григорьева В.А., Айламазян Э.К., Тарасова М.А. и др. Гинекологическая эндокринология. 2004. 6 (5).
- Зайдиева Я.З. Гормонопрофилактика и коррекция системных нарушений у женщин в перименопаузе. Автореф. дисс. докт. мед. наук. М., 1997.
- Кулаков В.И., Вихляева Е.М. Менопаузальный синдром (клиника, диагностика, профилактика и заместительная гормональная терапия). М., 1996.
- Прилепская В.Н. Контрацепция в различные возрастные периоды жизни женщины. М., 1998. С. 30-53.
- Прилепская В.Н., Меживитинова Е.А., Тагиева А.В. Внутриматочная контрацепция. М, 2000.
- Острейкова Л.И. Клинические аспекты применения внутриматочной левоноргестрел-рилизинг системы у женщин в пременопаузе. Автореф.канд. мед. наук. М.,2002
- Andersson JK, Rybo G. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. Br J Obstet Gynecol 1990; 97(8): 690-4.
- Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception 1994; 49(1): 56-72.
- Backman T, Rauramo I, Jaakkola K, et al. Use of the levonorgestrel-releasing intrauterine system and breast cancer. Obstet Gynecol 2005; 106(4): 813-7.
- Barbosa I, Bakos O, Olsson S et al. Ovarian function during use of a levonorgestrel-releasing IUD. Contraception 1990; 42(1): 51-66.
- Barrington J, Bowen-Simpkins P. The levonorgestrel intrauterine system in the management of menorrhagia. Br J Obstet Gynaecol 1997; 104(5): 614-6.
- Chavez NF, Stewart EA.Medical treatment of uterine fibroids. Clin Obstet Gynecol 2001; 44(2): 372-84.
- Coleman M, Cowan L, Farquhar C. The Levonorgestrel-Releasing Intrauterine Device: A Wider Role Than Contraception. Aust NZ Obstet Gynaecol 1997; 37 (2): 195-201.
- Critchley H, Wang H, Kelly R et al. Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system. Hum Reprod 1998; 13(5): 1210-710.
- Crook D, Cust M, Gangar K et al. Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on serum lipids and lipoproteins. Am J Obstet Gynecol 1992; 166: 950-5.
- Crosignani P, Vercellini P, Mosconi P et al. Levonorgestrel-releasing intrauterine device versus hysteroscopic endometrial resection in the treatment of dysfunctional uterine bleeding. Obstet Gynecol 1997; 90: 257-63.
- Faundes A, Alvarez F, Brache V, Tejada A. The role of the levonorgestrel intrauterine device in the prevention and treatment of iron deficiency anemia during fertility regulation. Int J Gyneacol Obstet 1988; 26: 429-33.
- Greendale G, Lee N, Arriola E. The menopause. Lancet 1999; 353(9152): 571-80.
- Heikkila M, Luukkainen T. Duration of breast-feeding and development of children after insertion of a levonorgestrel-releasing intrauterine contraceptive device. Contraception 1982; 25(3): 279-92.
- Hurk P, O'Brien S. Non-contraceptive use of the levonorgestrel-releasing intrauterine system. Obstet Gynaecol 1999; 1(1): 13-9.
- Irvine G, Campbell-Brown M, Lumsden M et al. Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. Br J Obstet Gynaecol 1998; 105(6): 592-8.
- Johansson E. Future aspects of the levonorgestrel-releasing intrayterine systetem. Gynecoly Forum 1998; 3(3): 311-32.
- Jonsson B, Landgren B, Enezoth P. Effects of various IUDs on the composition of cervical mucus. Contraception 1991; 43: 447-58.
- Klein N, Soules M. Endocrine changes of the perimenopause. Clin Obstet Gynecol 1998; 41(4): 912-20.
- Kubba A. Contraception: a review. Int J Clin Pract 1998; 52(2): 102-5.
- Lahteenmaki P. Health benefits of a levonorgestrel-releasing IUD (abstract). 7th European Congress of Gynaecology and Obstetric, 1992, 28 June - 1 July, Helsinki, Finland.
- Lahteenmaki P, Bardin C, Eloma K et al. Selection and performance of the levonorgestrel-releasing intrauterine system. Acta Obstet Gynecol Scand 1997; 164: 69-74.
- Luukkainen T, Allonen H, Haukkamaa M et al. Five years' experience with levonorgestrel-releasing IUDs. Contraception 1986; 33(2): 139-48.
- Mandelin E, Koistinen H, Koistinen R. et al. Levonorgestrel-releasind intrauterine device-wearing women express contraceptive glycodelin A in endometrium during midcycle: another contraceptive mechanism? Hum Reprod 1997; 12(12): 2671-5.
- Hampton NR, Rees MC et al. Levonorgestrel intrauterine system (LNG-IUS) with conjugated oral equine estrogen: a successful regimen for HRT in perimenopausal women. Hum Reprod 2005, 20(9): 2653-60.
- Nilsson C, Lahteenmaki P, Luukkainen T. Patterns of ovulation and bleeding with a low levonorgestrel-releasing intrauterine device. Contraception 1980; 21: 155-64.
- Pakarinen P, Lahteenmaki P, Rutanen E. The effect of intrauterine and oral levonorgestrel administration on serum concentrations of sex hormone-binding globulin, insulin and insulin-like growth factor binding protein-1. Acta Obstet Gynaecol Scand 1999; 78 (5): 423-8.
- Pekonen F, Nyman R, Lahteenmaki P et al. Intrauterine progestin induces continuous insulin-like growth factor-binding protein-1 production in the human endometrium. J Clin Endocrinol Metab 1992; 75(2): 660-4.
- Petta C. A. et al. Hum Reprod 2005; 5 (3): 1-6.
- Rutanen E. Endometrial response to intrauterine release of levonorgestrel Gynaecol Forum 1998; 3(3): 11-3.
- Rybo G. Tretment of menorrhagia using intrauterine administration of levonorgestrel Gynecol Forum 1998; 3(3): 20-2.
- Scholten P, Eykeren M, Christiaens G et al. Menstrual blood loss with levonorgestrel Nova-T and multiload Cu 250 intrauterine devices (thesis), Utrecht: University Hospital 1989; 35-45.
- Steinberg K, Thacker S, Smith J et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1990; 265: 1985-90.
- Stewart A et al. The effectiveness of the levonorgestrel-releasing intrauterine system in menorrhagia: a systematic review. BJOG: an international Journal of Obstetrics & Gynecology, 2001; 108: 74-86.
- Stovall TG, Ling FW, Henry LC et al A randomized trial evaluating leuprolide acetate before hysterectomy as treatment for leiomyomas. Am J Obstet Gynecol 1991; 164: 1420-3.
- http://www.pharmateca.ru/cgi-bin/statyi.pl?sid=2488&mid=1085056570&magid=185&full=1